[go: up one dir, main page]

MX345316B - Métodos y composiciones para diagnóstico y tratamiento del cáncer. - Google Patents

Métodos y composiciones para diagnóstico y tratamiento del cáncer.

Info

Publication number
MX345316B
MX345316B MX2014012968A MX2014012968A MX345316B MX 345316 B MX345316 B MX 345316B MX 2014012968 A MX2014012968 A MX 2014012968A MX 2014012968 A MX2014012968 A MX 2014012968A MX 345316 B MX345316 B MX 345316B
Authority
MX
Mexico
Prior art keywords
nucleic acid
peptide
amount
agent
detection
Prior art date
Application number
MX2014012968A
Other languages
English (en)
Inventor
Sahin Ugur
Türeci Özlem
Koslowski Michael
Walter Korden
Wöll Stefan
Helftenbein Gerd
Oprea Gabriela-Elena
Original Assignee
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09002452A external-priority patent/EP2221375A1/en
Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag
Publication of MX345316B publication Critical patent/MX345316B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para asistir en el diagnóstico, detección o monitorea de una enfermedad tumoral, caracterizado porque el método comprende la detección de y/o determinación d ela cantidad de uno o más parámetros seleccionados del grupo que consiste de: (i) un ácido nucleico que codifica un antígeno tumoral, y (ii) un péptido que comprende la secuencia de aminoácidos de un antígeno tumoral, en una muestra biológica aislada de un paciente, en donde dicho antígeno tumoral comprende una secuencia de aminoácidos codificada por un ácido nucleico que comprende la secuencia de ácido nucleico de la SEQ ID NO: 1 del listado de secuencia so una variante de dicho ácido nucleico que es al menos 90% idéntico de SEQ ID NO: 1, en donde la detección y/o determinación de la cantidad comprende: (A) poner en contacto la muestra biológica con un agente que enlaza específicamente al ácido nucleico o el péptido a detectarse y/o la cantidad de la cual se va a determinar; y (B) detectar la formación de y/o determinar la cantidad de un complejo entre el agente y el ácido nucleico o el péptido a detectarse o la cantidad de la cual se va a determinar: en donde (a) el agente que enlaza específicamente al ácido nucleico que comprende un oligonucleótido, que hibridiza específicamente al ácido nucleico, y (b) el agente que enlaza específicamente al péptido que comprende un anticuerpo enlazado específicamente al péptido.
MX2014012968A 2009-02-20 2010-02-19 Métodos y composiciones para diagnóstico y tratamiento del cáncer. MX345316B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15416709P 2009-02-20 2009-02-20
EP09002452A EP2221375A1 (en) 2009-02-20 2009-02-20 Methods and compositions for diagnosis and treatment of cancer
US23184309P 2009-08-06 2009-08-06
EP09010164 2009-08-06
US26013509P 2009-11-11 2009-11-11
EP09014135 2009-11-11
PCT/EP2010/001062 WO2010094499A1 (en) 2009-02-20 2010-02-19 Methods and compositions for diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
MX345316B true MX345316B (es) 2017-01-23

Family

ID=42114454

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2011008430A MX2011008430A (es) 2009-02-20 2010-02-19 Metodos y composiciones para diagnostico y tratamiento del cancer.
MX2017001051A MX361432B (es) 2009-02-20 2010-02-19 Métodos para diagnóstico del cáncer.
MX2014012968A MX345316B (es) 2009-02-20 2010-02-19 Métodos y composiciones para diagnóstico y tratamiento del cáncer.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2011008430A MX2011008430A (es) 2009-02-20 2010-02-19 Metodos y composiciones para diagnostico y tratamiento del cancer.
MX2017001051A MX361432B (es) 2009-02-20 2010-02-19 Métodos para diagnóstico del cáncer.

Country Status (25)

Country Link
US (4) US9809815B2 (es)
EP (2) EP2398902B1 (es)
JP (1) JP5808254B2 (es)
KR (3) KR102152997B1 (es)
CN (2) CN102325885A (es)
AU (2) AU2010215700B2 (es)
BR (1) BRPI1008564B1 (es)
CA (1) CA2750985C (es)
DK (1) DK2398902T3 (es)
ES (1) ES2963717T3 (es)
FI (1) FI2398902T3 (es)
HR (1) HRP20231525T1 (es)
HU (1) HUE064745T2 (es)
IL (4) IL214256A0 (es)
LT (1) LT2398902T (es)
MX (3) MX2011008430A (es)
NZ (1) NZ594480A (es)
PL (1) PL2398902T3 (es)
PT (1) PT2398902T (es)
RS (1) RS64937B1 (es)
SG (3) SG10201402493UA (es)
SI (1) SI2398902T1 (es)
SM (1) SMT202300421T1 (es)
WO (1) WO2010094499A1 (es)
ZA (1) ZA201105471B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
PT2398902T (pt) 2009-02-20 2023-12-05 Astellas Pharma Inc Métodos e composições para diagnóstico e tratamento de cancro
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
UA117799C2 (uk) 2009-11-11 2018-10-10 Ґанімед Фармасьютікалз Аґ Моноклональне антитіло, специфічне до клаудину 6 (cldn6)
WO2011113546A1 (en) 2010-03-16 2011-09-22 Biontech Ag Tumor vaccination involving a humoral immune response against self-proteins
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
NZ724296A (en) 2011-05-13 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US10329353B2 (en) * 2013-03-05 2019-06-25 Board Of Regents, The University Of Texas System Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CA2928671A1 (en) 2013-11-06 2015-05-14 Stemcentrx, Inc. Novel anti-claudin antibodies and methods of use
LT3708579T (lt) 2014-04-01 2024-07-25 Biontech Cell & Gene Therapies Gmbh Klaudinui-6 specifiniai imunoreceptoriai ir t ląstelių epitopai
CN116999572A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体－药物偶联物、药物组合物及其在制备治疗肿瘤的药物中的应用
WO2024118771A1 (en) 2022-11-30 2024-06-06 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO2000073348A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2339043A1 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
CA2349158A1 (en) 1998-11-03 2000-05-11 Adherex Technologies, Inc. Compounds and methods for modulating claudin-mediated functions
EP1140970A4 (en) 1998-12-17 2003-10-22 Human Genome Sciences Inc 47 HUMAN SECRETED PROTEINS
KR100358062B1 (ko) * 1998-12-30 2003-01-24 주식회사 하이닉스반도체 플래쉬메모리셀및그의제조방법
CA2361743A1 (en) 1999-02-22 2000-08-31 Michael G. Walker Genes associated with diseases of the colon
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1067182A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
CA2402563A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001051513A2 (en) 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001278852A1 (en) 2000-06-23 2002-01-08 Genentech Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1309685A2 (en) 2000-07-20 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1354040A2 (en) 2000-07-20 2003-10-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7351802B2 (en) 2000-07-25 2008-04-01 Genentech, Inc. PRO19672 antibodies
EP1311530A4 (en) 2000-08-03 2004-10-06 Wim-Van Schooten PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040033493A1 (en) * 2001-01-31 2004-02-19 Tchernev Velizar T. Proteins and nucleic acids encoding same
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
CA2379661A1 (en) 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US20070207142A1 (en) 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP1594447A2 (en) 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004035607A2 (en) 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
AU2003303144A1 (en) 2002-10-18 2004-07-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
BRPI0410875A (pt) 2003-05-30 2006-07-04 Centocor Inc método de inibição do crescimento de tumor com anticorpos de fator antitecido
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20080305493A1 (en) 2004-03-08 2008-12-11 Avalon Pharmaceuticals Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
DE102005025041A1 (de) 2005-05-30 2006-12-07 Bell Flavors & Fragrances Duft Und Aroma Gmbh Mittel zur Anwendung in Spülmaschinen sowie Vorrichtung für dessen dosierte Einbringung während der Spül- und Trocknungsphasen
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP5632582B2 (ja) 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
EP2138576A4 (en) 2007-03-16 2011-02-23 Kyowa Hakko Kirin Co Ltd ANTI-CLAUDIN-4 ANTIBODY
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) * 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
MX2010007500A (es) 2008-01-11 2010-10-20 Univ Tokyo Anticuerpo anti-cldn6.
JP2011516580A (ja) 2008-04-11 2011-05-26 バイオノボ・インコーポレーテッド トウサイカチｇｌｅｄｉｔｓｉａｓｉｎｅｎｓｉｓｌａｍの抽出物を用いる抗癌方法
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
DE102009026973A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Bremsanlage für ein Kraftfahrzeug und Verfahren zu ihrer Steuerung
JP2010178650A (ja) 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
PT2398902T (pt) 2009-02-20 2023-12-05 Astellas Pharma Inc Métodos e composições para diagnóstico e tratamento de cancro
DE102009010019B4 (de) 2009-02-21 2012-05-31 Jos. Schneider Optische Werke Gmbh Verfahren zum berührungslosen Messen der Topographie
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
UA117799C2 (uk) 2009-11-11 2018-10-10 Ґанімед Фармасьютікалз Аґ Моноклональне антитіло, специфічне до клаудину 6 (cldn6)
WO2011105551A1 (ja) 2010-02-26 2011-09-01 国立大学法人大阪大学 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
NZ724296A (en) 2011-05-13 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US10018630B2 (en) 2011-09-07 2018-07-10 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen für gynäkologisches Malignom und deren Verwendung
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells

Also Published As

Publication number Publication date
SG173444A1 (en) 2011-09-29
US11473085B2 (en) 2022-10-18
BRPI1008564B1 (pt) 2021-10-05
RS64937B1 (sr) 2024-01-31
IL258794B (en) 2019-06-30
KR20110128316A (ko) 2011-11-29
EP2398902A1 (en) 2011-12-28
PT2398902T (pt) 2023-12-05
AU2010215700A1 (en) 2011-08-18
IL236516B (en) 2018-05-31
WO2010094499A1 (en) 2010-08-26
MX2011008430A (es) 2011-09-29
SMT202300421T1 (it) 2024-01-10
LT2398902T (lt) 2023-12-27
AU2016201051B2 (en) 2018-02-08
SG10201402493UA (en) 2014-10-30
EP4285911A2 (en) 2023-12-06
CN102325885A (zh) 2012-01-18
KR20180098701A (ko) 2018-09-04
HRP20231525T1 (hr) 2024-03-15
IL258794A (en) 2018-06-28
MX361432B (es) 2018-12-05
US20190169614A1 (en) 2019-06-06
JP2012518609A (ja) 2012-08-16
KR102152997B1 (ko) 2020-09-07
IL236516A0 (en) 2015-02-26
US20230193261A1 (en) 2023-06-22
SG10202005849RA (en) 2020-07-29
ES2963717T3 (es) 2024-04-01
IL267342A (en) 2019-08-29
BRPI1008564A2 (pt) 2018-02-27
AU2010215700B2 (en) 2015-11-19
PL2398902T3 (pl) 2024-02-26
AU2016201051A1 (en) 2016-03-10
IL214256A0 (en) 2011-09-27
DK2398902T3 (da) 2023-12-04
KR102340685B1 (ko) 2021-12-17
CN107028969A (zh) 2017-08-11
FI2398902T3 (fi) 2023-11-28
ZA201105471B (en) 2012-10-31
SI2398902T1 (sl) 2024-04-30
JP5808254B2 (ja) 2015-11-10
CA2750985A1 (en) 2010-08-26
US9809815B2 (en) 2017-11-07
KR20200105549A (ko) 2020-09-07
EP4285911A3 (en) 2024-04-10
US20180119146A1 (en) 2018-05-03
NZ594480A (en) 2013-11-29
HUE064745T2 (hu) 2024-04-28
CA2750985C (en) 2022-07-19
EP2398902B1 (en) 2023-10-04
IL267342B (en) 2021-12-01
US20110300144A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
MX345316B (es) Métodos y composiciones para diagnóstico y tratamiento del cáncer.
RU2485974C2 (ru) Идентификация опухолевых антигенов для диагностики и терапии
MX337991B (es) Metodo para detectar cancer.
JP2008249727A5 (es)
UA98585C2 (uk) Антитіло, яке специфічно зв'язується з нейропіліном-1 (nrp1)
RU2015147287A (ru) Гуманизированные антитела против axl
AR101848A1 (es) Anticuerpos de anti-b7-h4 e inmunoconjugados
JP2016536330A5 (es)
AR088827A1 (es) Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer
JP2015533788A5 (es)
JP2012115275A5 (es)
ZA200805787B (en) Detection of cancer by elevated levels of BCL-2
NZ602056A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2010514805A5 (es)
JP2010521655A5 (es)
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
JP2017538412A5 (es)
NZ598035A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DE602006012995D1 (de) Brustkrebsdiagnoseverfahren
JP2012518163A5 (es)
WO2010045495A3 (en) Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
JP2019529346A5 (es)
NZ599773A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
ATE547523T1 (de) Vegfr-varianten und deren verwendung bei der diagnose und behandlung von mit schwangerschaft assoziierten medizinischen leiden